Thursday, January 31, 2013

FDA approves Bayer antimicrobial for swine respiratory disease control


    Baytril 100 (enrofloxacin) Injectable, manufactured by Bayer HealthCare LLC, Animal Health division recently received Food and Drug Administration approval for the treatment and control of swine respiratory disease associated with bacterial pathogens Mycoplasma hyopneumoniae (M. Hyo) and Bordetella bronchiseptica (B. bronchiseptica).
    Baytril 100 is an effective treatment tool in pigs which are eight to 12 weeks along in the  finishing stage to help knock down the "10-week wall" of respiratory disease, according to Bayer. In addition, producers may use Baytril 100 as a health management tool to control swine respiratory disease in the nursery and the farrowing barn.
    Baytril 100 is the only approved fluoroquinolone class of products labeled for use in swine. It is bactericidal, which is a term used to describe classes of drugs that reduce bacterial populations. Due to the mode of action of Baytril 100, it kills six major swine respiratory disease-causing bacteria in both the resting and growth phases of bacteria development by essentially killing the "heart" of the bacteria. Baytril 100 is approved for treating and controlling swine respiratory disease associated with Mycoplasma hyopneumoniae (M. hyo), Bordetella bronchiseptica (B. bronchiseptica), Actinobacillus pleuropneumoniae (APP), Pasteurella multocida, Haemophilus parasuis and Streptococcus suis.

No comments:

Post a Comment